Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
J Immunol ; 164(7): 3563-72, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10725711

ABSTRACT

Experimental autoimmune encephalomyelitis (EAE) is induced in the SJL/J mouse by adoptive transfer of activated proteolipid protein peptide (PLP) 139-151-specific Th1 cells. T cells responding to altered peptide ligands (APL) of PLP, previously shown to induce Th2 differentiation and regulate disease in PLP-immunized mice, do not transfer EAE. However, the exact mechanism of disease regulation by APL-specific T cells has not been elucidated. In this report, we show that 1F1, a Th2 clone specific for an APL of PLP139-151 can prevent adoptive transfer of EAE when cocultured with PLP-encephalitogenic spleen cells (PLP-spleen). Cytokines from activated 1F1 cells were detected by hybridization of mRNA to oligonucleotide arrays (DNA chip) and by ELISA. The Th2 cytokines found to be present at the highest protein and mRNA levels were evaluated for their role in suppression of adoptive transfer of EAE from PLP-activated spleen cell cultures. Abs to individual cytokines in 1F1 PLP-spleen cocultures suggested that IL-4, IL-13, and TGF-beta played a significant role in suppressing EAE. Abs to the combination of IL-4, IL-10, IL-13, and TGF-beta completely neutralized the protective effect of 1F1. Addition of Th2 cytokines to PLP-spleen cultures showed that IL-13 and TGF-beta were each individually effective and low levels of IL-4 synergized with IL-13 to inhibit disease transfer. IL-5, IL-9, and IL-10 had little or no effect whereas GM-CSF slightly enhanced EAE. Our results demonstrate that Th2 cytokines derived from APL-specific Th2 cells can effectively down-regulate the encephalitogenic potential of PLP-spleen cells if present during their reactivation in culture.


Subject(s)
Adoptive Transfer , Down-Regulation/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Interleukin-10/physiology , Interleukin-13/physiology , Interleukin-4/physiology , Oligopeptides/immunology , Th2 Cells/immunology , Transforming Growth Factor beta/physiology , Animals , Cell Line , Clone Cells , Coculture Techniques , Cytokines/antagonists & inhibitors , Cytokines/metabolism , Down-Regulation/genetics , Drug Combinations , Drug Synergism , Encephalomyelitis, Autoimmune, Experimental/prevention & control , Female , Humans , Immunosuppressive Agents/pharmacology , Interleukin-10/genetics , Interleukin-10/pharmacology , Interleukin-13/genetics , Interleukin-13/pharmacology , Interleukin-4/genetics , Interleukin-4/pharmacology , Ligands , Lymphocyte Activation , Mice , Mice, Inbred Strains , Myelin Proteolipid Protein/genetics , Myelin Proteolipid Protein/immunology , Myelin Proteolipid Protein/metabolism , Oligopeptides/genetics , Oligopeptides/metabolism , Peptide Fragments/genetics , Peptide Fragments/immunology , Peptide Fragments/metabolism , Th2 Cells/metabolism , Transforming Growth Factor beta/genetics
2.
J Immunol ; 145(2): 607-15, 1990 Jul 15.
Article in English | MEDLINE | ID: mdl-2142182

ABSTRACT

Cultured human monocytes undergo a process of differentiation and maturation lasting 5 to 10 days that ultimately leads to the appearance of large macrophage-like cells. This differentiation is growth factor dependent: of all the cytokines tested, only macrophage colony-stimulating factor (M-CSF), granulocyte/macrophage-CSF (GM-CSF), and IL-3 proved capable of supporting the differentiation and the long term survival of the macrophage-like cells. Although all three cytokines yield cells with macrophage characteristics, cells developed in M-CSF have features distinct from those matured in either IL-3 or GM-CSF. At the morphologic level, the M-CSF-supported monocyte cultures yield elongated, spindle-shaped cells whereas those supported with IL-3 or GM-CSF yielded round cells with distinct nuclei. All three macrophage populations expressed similar levels of HLA-DR, CD11b, and CD11c, but the M-CSF-treated cultures yielded more CD14+ and CD16+ (Fc gamma RIII) cells. All three cell populations developed capacity for antibody-dependent cellular cytotoxicity (ADCC) as well as antibody-independent cytotoxicity with peak activity achieved after 8 to 12 days in culture. ADCC capacity developed earliest and the level of activity was usually greatest in the M-CSF-treated cultures, possibly correlating with the higher level of expression of CD16. Our findings indicate that any of these cytokines, but particularly M-CSF, may be useful clinically in enhancing the tumoricidal capacity of tumor-specific mAb through augmentation of macrophage capacity for ADCC.


Subject(s)
Colony-Stimulating Factors/pharmacology , Growth Substances/pharmacology , Interleukin-3/pharmacology , Macrophages/immunology , Monocytes/cytology , Antibody-Dependent Cell Cytotoxicity , Antigens, Differentiation/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Cell Differentiation/drug effects , Cells, Cultured , Granulocyte-Macrophage Colony-Stimulating Factor , Humans , Immunity, Cellular , In Vitro Techniques , Macrophage Colony-Stimulating Factor , Receptors, Fc/analysis , Receptors, IgG , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL